Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

2.56USD
19 Jul 2017
Change (% chg)

-- (--)
Prev Close
$2.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,234
52-wk High
$6.24
52-wk Low
$2.52

SNSS.OQ

Chart for SNSS.OQ

About

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia... (more)

Overall

Beta: 1.74
Market Cap(Mil.): $54.94
Shares Outstanding(Mil.): 21.46
Dividend: --
Yield (%): --

Financials

  SNSS.OQ Industry Sector
P/E (TTM): -- 206.20 15.78
EPS (TTM): -2.25 -- --
ROI: -136.29 -7.19 -8.29
ROE: -- -8.69 -7.91

BRIEF-Balyasny Asset Management reports 9.32 pct passive stake in Sunesis Pharmaceuticals

* Balyasny Asset Management reports a 9.32 percent passive stake in Sunesis Pharmaceuticals Inc as of June 23, 2017 - SEC filing Source text: (http://bit.ly/2tRWgIv) Further company coverage:

Jul 05 2017

BRIEF-Sunesis Pharmaceuticals amends loan agreement

* Sunesis Pharmaceuticals Inc - on June 30, 2017, co entered into an amendment, or amendment, to loan and security agreement dated march 31, 2016

Jun 30 2017

BRIEF-Sunesis Pharmaceuticals files for mixed shelf of up to $200 mln

* Files for mixed shelf of up to $200 million - SEC filing Source text for Eikon: Further company coverage:

Jun 08 2017

BRIEF-Sunesis Pharmaceuticals qtrly basic and diluted loss per share $0.47

* Sunesis pharmaceuticals reports first quarter 2017 financial results and recent highlights

May 08 2017

BRIEF-Sunesis Pharma announces withdrawal of European MAA for vosaroxin

* Sunesis Pharmaceuticals announces withdrawal of European Marketing Authorization Application (MAA) for vosaroxin as a treatment for relapsed/refractory AML

May 01 2017

BRIEF-Aimmune Therapeutics appoints Eric Bjerkholt as CFO

* Aimmune Therapeutics appoints Eric Bjerkholt as Chief Financial Officer

Apr 13 2017

BRIEF-Sunesis Pharmaceuticals says CFO Eric Bjerkholt to resign to pursue another opportunity - SEC Filing

* On April 7, CFO Eric Bjerkholt informed co of his resignation from all of his positions at co effective as of April 27, 2017

Apr 12 2017

BRIEF-Sunesis Pharmaceuticals reports presentation of preclinical study of btk inhibitor sns-062

* Sunesis Pharmaceuticals announces presentation of the ohio state university-sponsored preclinical study of btk inhibitor sns-062 at aacr annual meeting

Apr 03 2017

BRIEF-Sunesis Pharmaceuticals provides update on EU marketing app for vosaroxin

* Sunesis pharmaceuticals announces submission of responses to ema day 180 list of outstanding issues for marketing authorization application for vosaroxin

Mar 22 2017

BRIEF-Sunesis Pharma announces clinical and regulatory updates to SNS-062 and vosaroxin programs

* Sunesis pharmaceuticals announces clinical and regulatory updates to SNS-062 and vosaroxin programs

Jan 23 2017

Competitors

Earnings vs. Estimates